Cambridge Cognition Holdings stock analysis
Cambridge Cognition Holdings (1M7) Stock Price & Analysis
1M7 Stock Chart & Stats
- Day’s Range
- EUR 0.30 - EUR 0.30
- 52-Week Range
- EUR 0.29 - EUR 0.48
- Previous Close
- EUR 0.30
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 17.78M
- Enterprise Value
- EUR 15.04M
- Total Cash (Recent Filing)
- EUR 582.00K
- Total Debt (Recent Filing)
- EUR 239.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.22
- Next Earnings
- May 05, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margins
Gross margins of roughly 74%–81% indicate the software and related services retain substantial value after direct costs. That provides a sound base for eventual operating leverage, although the company still needs to bring operating expenses into line with its revenue scale.
Improved Balance Sheet
Debt fell from £1.91m in 2024 to £0.86m in 2025, while equity rose to £2.99m. This materially improves resilience and reduces balance-sheet pressure, giving the company more flexibility to sustain operations and pursue its digital health activities.
Reduced Cash Burn
Although free cash flow remains negative, the 2025 operating outflow of £0.23m and free-cash-flow outflow of £0.26m were far smaller than the roughly £3.1m outflow in 2024. The reduced burn is an important step toward a more sustainable funding profile.
Bears Say
Persistent Losses
Operating and net losses have persisted for four consecutive years from 2022 through 2025, after profitability in 2021. This indicates that the current revenue base is not yet sufficient to support the cost structure, limiting internal funding capacity and delaying dependable shareholder returns.
Revenue Decline
Revenue declined from £13.5m in 2023 to £10.3m in 2024 and £9.4m in 2025, despite a small 3.8% increase in 2025. The fall from the peak reduces operating leverage and makes it harder for fixed costs to be absorbed or profitability to recover.
Negative Free Cash Flow
Free cash flow remained negative through 2023–2025, including a £0.26m outflow in 2025. Even with the improvement from 2024, the business is still not self-funding, so continued investment and operations remain dependent on preserving or obtaining sufficient financial resources.
Cambridge Cognition Holdings News
1M7 FAQ
What was Cambridge Cognition Holdings’s price range in the past 12 months?
What is Cambridge Cognition Holdings’s market cap?
When is Cambridge Cognition Holdings’s upcoming earnings report date?
How were Cambridge Cognition Holdings’s earnings last quarter?
Is Cambridge Cognition Holdings overvalued?
Does Cambridge Cognition Holdings pay dividends?
What is Cambridge Cognition Holdings’s EPS estimate?
How many shares outstanding does Cambridge Cognition Holdings have?
What happened to Cambridge Cognition Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cambridge Cognition Holdings?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cambridge Cognition Holdings
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Robert Baker
- Employees
- 74
- Website
- www.cambridgecognition.com
- Address
- Tunbridge Court, Cambridge, CAM, CB25 9TU, GB
Cambridge Cognition Holdings (1M7) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |








